Cargando…

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial

The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic function and peripheral arterial conditions in women with overactive bladder syndrome (OAB). All consecutive women with OAB were randomized to receive 12 weeks of mirabegron 25 mg or solifenacin 5 mg once per day. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Sheng-Mou, Tu, Fung-Chao, Su, Ta-Chen, Wu, Pei-Chi, Lin, Ho-Hsiung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392788/
https://www.ncbi.nlm.nih.gov/pubmed/35987885
http://dx.doi.org/10.1038/s41598-022-18391-6
_version_ 1784771141141790720
author Hsiao, Sheng-Mou
Tu, Fung-Chao
Su, Ta-Chen
Wu, Pei-Chi
Lin, Ho-Hsiung
author_facet Hsiao, Sheng-Mou
Tu, Fung-Chao
Su, Ta-Chen
Wu, Pei-Chi
Lin, Ho-Hsiung
author_sort Hsiao, Sheng-Mou
collection PubMed
description The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic function and peripheral arterial conditions in women with overactive bladder syndrome (OAB). All consecutive women with OAB were randomized to receive 12 weeks of mirabegron 25 mg or solifenacin 5 mg once per day. Heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, blood pressure, and heart rate were compared between the two groups. There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variability examination. Systolic blood pressure (median: − 4.5 to − 5.5 mmHg) and diastolic blood pressure (median: − 0.5 to − 3.5 mmHg) decreased after solifenacin treatment, and heart rate (median: + 2 bpm) increased after mirabegron treatment, despite of no between-group difference. In addition, posttreatment heart rate variability, cardio-ankle vascular index, and ankle-brachial pressure index did not differ compared with baseline; and there were no between-group differences. In conclusion, solifenacin might decrease blood pressure, and mirabegron might increase heart rate. Nonetheless, there were no significant impacts of 12-week mirabegron versus solifenacin treatment on autonomic function and arterial stiffness.
format Online
Article
Text
id pubmed-9392788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93927882022-08-22 Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial Hsiao, Sheng-Mou Tu, Fung-Chao Su, Ta-Chen Wu, Pei-Chi Lin, Ho-Hsiung Sci Rep Article The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic function and peripheral arterial conditions in women with overactive bladder syndrome (OAB). All consecutive women with OAB were randomized to receive 12 weeks of mirabegron 25 mg or solifenacin 5 mg once per day. Heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, blood pressure, and heart rate were compared between the two groups. There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variability examination. Systolic blood pressure (median: − 4.5 to − 5.5 mmHg) and diastolic blood pressure (median: − 0.5 to − 3.5 mmHg) decreased after solifenacin treatment, and heart rate (median: + 2 bpm) increased after mirabegron treatment, despite of no between-group difference. In addition, posttreatment heart rate variability, cardio-ankle vascular index, and ankle-brachial pressure index did not differ compared with baseline; and there were no between-group differences. In conclusion, solifenacin might decrease blood pressure, and mirabegron might increase heart rate. Nonetheless, there were no significant impacts of 12-week mirabegron versus solifenacin treatment on autonomic function and arterial stiffness. Nature Publishing Group UK 2022-08-20 /pmc/articles/PMC9392788/ /pubmed/35987885 http://dx.doi.org/10.1038/s41598-022-18391-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hsiao, Sheng-Mou
Tu, Fung-Chao
Su, Ta-Chen
Wu, Pei-Chi
Lin, Ho-Hsiung
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title_full Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title_fullStr Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title_full_unstemmed Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title_short Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
title_sort impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392788/
https://www.ncbi.nlm.nih.gov/pubmed/35987885
http://dx.doi.org/10.1038/s41598-022-18391-6
work_keys_str_mv AT hsiaoshengmou impactofmirabegronversussolifenacinonautonomicfunctionandarterialstiffnessinfemaleoveractivebladdersyndromearandomizedcontrolledtrial
AT tufungchao impactofmirabegronversussolifenacinonautonomicfunctionandarterialstiffnessinfemaleoveractivebladdersyndromearandomizedcontrolledtrial
AT sutachen impactofmirabegronversussolifenacinonautonomicfunctionandarterialstiffnessinfemaleoveractivebladdersyndromearandomizedcontrolledtrial
AT wupeichi impactofmirabegronversussolifenacinonautonomicfunctionandarterialstiffnessinfemaleoveractivebladdersyndromearandomizedcontrolledtrial
AT linhohsiung impactofmirabegronversussolifenacinonautonomicfunctionandarterialstiffnessinfemaleoveractivebladdersyndromearandomizedcontrolledtrial